Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Maraviroc (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Pharmacodynamics
- Acronyms MIP
- 15 Nov 2017 Status changed from recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 04 Aug 2016 Planned End Date changed from 1 Jan 2020 to 1 Jan 2022.